NRx Pharmaceuticals, Inc. (NRXP)
| Market Cap | 149.20M +202.0% |
| Revenue (ttm) | 3.39M |
| Net Income | -23.48M |
| EPS | -0.78 |
| Shares Out | 41.91M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 610,168 |
| Open | 3.520 |
| Previous Close | 3.510 |
| Day's Range | 3.440 - 3.600 |
| 52-Week Range | 1.620 - 5.055 |
| Beta | 2.18 |
| Analysts | Strong Buy |
| Price Target | 38.25 (+974.44%) |
| Earnings Date | Aug 17, 2026 |
About NRXP
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for in... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for NRXP stock is "Strong Buy." The 12-month stock price target is $38.25, which is an increase of 974.44% from the latest price.
News
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET
Key recent and second quarter highlights include: Completed first-cycle FDA review of the Company's ANDA for preservative-free ketamine with no drug-related major deficiencies. The sole remaining item...
NRx Pharmaceuticals Quarterly report: Q2 2026
NRx Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 14, 2026.
NRx Pharmaceuticals Earnings release: Q2 2026
NRx Pharmaceuticals released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
NRx Pharmaceuticals Transcript: Status update
FDA review of the preservative-free ketamine ANDA is nearly complete, with only a minor manufacturing attestation pending and no major deficiencies identified. Manufacturing is being scaled up to five million units, and commercial preparations are underway to address U.S. drug shortages and capture significant market share.
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans
MIAMI, Aug. 07, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host ...
FDA completes review of NRx Pharmaceuticals preservative-free ketamine ANDA
NRx Pharmaceuticals (NRXP) announced that the FDA has completed first-cycle review of the company’s ANDA for its preservative-free ketamine, with no major deficiencies related to the drug product, ing...
FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval
FDA identified no major deficiencies related to the ketamine drug product, ingredients, proposed labeling, CMC, or other drug-related review matters. Remaining item relates to manufacturer certificati...
NRx Pharmaceuticals issues response to Kadima statements
NRx Pharmaceuticals (NRXP) issued the following statement in response to recent public claims made by Kadima Neuropsychiatry Institute. “Kadima issued a public statement on June 24, 2026 making a seri...
NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute
WILMINGTON, Del., June 25, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx” or the “Company”) today issued the following statement in response to recent public claims made by K...
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
First Zeta-navigated TMS treatments have begun at HOPE Therapeutics clinics in West Palm Beach and Sarasota, Florida, marking the transition from research deployment to active patient care AI-powered,...
Kadima Neuropsychiatry Institute alleges NRx breached contract
Kadima Neuropsychiatry Institute and its founder, Dr. David Feifel, said the have filed a complaint against NRx Pharmaceuticals (NRXP) in San Diego County Superior Court, alleging breach of contract a...
Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition
SAN DIEGO--(BUSINESS WIRE)--Kadima Neuropsychiatry Institute and its founder, Dr. David Feifel, have filed a complaint against NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and two of its subsidiaries in S...
ZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics
SARASOTA, Fla, and BOSTON, June 23, 2026 /PRNewswire/ -- ZETA SURGICAL and HOPE Therapeutics, an NRx Pharmaceuticals company (Nasdaq: NRXP), today announced the first patient treatment with the FDA-cl...
NRx Pharmaceuticals announces FDA grant of expanded access protocol for NRX-101
NRx Pharmaceuticals (NRXP) announced the approval by FDA of an intermediate population expanded access protocol for the use of NRX-101, a fixed dose combination of D-cycloserine and lurasidone for the...
NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression
WILMINGTON, Del., June 22, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a biopharmaceutical company that focuses on neuroplastic therapies for depression, PTSD, and related condi...
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.
MIAMI, June 05, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq:NRXP, “the Company”) announces the presentation of a peer-reviewed poster at the 2026 American Society of Clinical Psychopharmacolo...
NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters' Option
Offering was led by B Group Capital with significant participation from, among others, Columbia Threadneedle Investments, Corbets Capital, Venture 76, and Mossrock Capital Offering was led by B Group ...
NRx Pharmaceuticals 5.7M share Spot Secondary priced at $3.50
Lucid Capital acted as sole book running manager for the offering.
NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
WILMINGTON, Del., June 03, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company, today announced the p...
NRx Pharmaceuticals announces common stock offering, no amount given
NRx Pharmaceuticals (NRXP) announced that it intends to offer shares of its common stock in an underwritten public offering. The company currently intends to use the net proceeds from the…
NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
WILMINGTON, Del., June 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company, today announced that ...
NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026
EMOCARE is a smartphone-based passive monitoring tool that generates a continuous, real-time measure of depression from patient voice, facial expression, motion, and screen behavior, and is the first ...
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
Deployment at HOPE's West Palm Beach clinic brings AI-powered, sub-millimetric image guidance to the delivery of Transcranial Magnetic Stimulation (TMS) for patients with Major Depressive Disorder and...
NRx Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw major regulatory and commercial progress, including advancing preservative-free ketamine toward FDA approval, expanding clinical operations, and acquiring new CNS assets. Net loss dropped 74% year-over-year, and $7 million was raised post-quarter.
NRx Pharmaceuticals Quarterly report: Q1 2026
NRx Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 18, 2026.